The Medical Advisor

Abstract Importance: Cancer remains the second leading cause of death in the United States, despite substantial advances in prevention, screening, and treatment. Objective: To synthesize current evidence and outline a realistic, data-driven roadmap for reducing cancer mortality and improving outcomes between 2026 and 2035. Evidence Review: Evidence was drawn from reports by the American Cancer Society, National Cancer Institute, and Centers for Disease Control and Prevention, as well as peer-reviewed studies in The New England Journal of Medicine , JAMA , and the Journal of the National Cancer Institute . Findings: The most impactful interventions include tobacco control, vaccination, evidence-based screening, precision oncology, and standardized care delivery. Prevention and early detection account for a substantial proportion of mortality reduction. Conclusions and Relevance: A comprehensive cancer strategy emphasizing prevention, early detection, and equitable delivery of evide...

A woman facing a lung transplant reversed her condition with a $30 over-the-counter treatment. Doctors told her she had no options. A new doctor suggested DMSO. Months later? Her lungs were CLEAR.  Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news in 2022: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. Buy on Amazon “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. Dr. James Miller, a former surgeon, liked to get to know his patients, so ...

Abstract Background: Despite advances in chemotherapy, targeted therapy, and immunotherapy, resistance remains a major barrier in oncology. Metabolic reprogramming and drug repurposing offer potential adjunctive strategies. Objective: To evaluate the integration of metabolic interventions and repurposed agents (ivermectin, mebendazole) with standard cancer therapies. Methods: Narrative review of PubMed-indexed literature and early clinical data. Results: Mebendazole shows safety and feasibility in combination with chemotherapy in a phase 1 glioma trial. Ivermectin demonstrates anticancer effects in preclinical models. Metabolic interventions show mixed but promising adjunctive effects. Evidence supports adjunctive—not replacement—use. Conclusion: Integrative metabolic oncology represents a promising but investigational strategy requiring randomized trials. Introduction Cancer metabolism, first described via the Warburg effect (7), is now recognized as dynamic and adaptable. Tumors can ...

Abstract Background: Cancer has historically been defined by genetic alterations driving uncontrolled proliferation. However, metabolic reprogramming is now recognized as a fundamental characteristic of malignant cells that supports survival, proliferation, and interaction with the tumor microenvironment. Recent reviews have conceptualized metabolic alterations as emerging hallmarks of cancer physiology. Objective: We propose a comprehensive set of metabolic hallmarks of cancer , synthesizing recent literature on glucose metabolism, mitochondrial function, metabolite signaling, and metabolic‑immune interactions. Methods: We integrated insights from high‑impact reviews in cancer metabolism (e.g., Cell Metabolism, Molecular Cancer, Frontiers in Oncology) to define ten metabolic hallmarks with mechanistic and clinical relevance. Results: The ten hallmarks include: (1) Aerobic glycolysis; (2) Mitochondrial reprogramming; (3) Lactate accumulation; (4) Metabolic immune suppression; ...

What Is Methylene Blue?  Methylene blue is the parent molecule for hydroxychloroquine and chloroquine, off-patent drugs commonly used to treat not only malaria but also COVID-19. Best known as a fish tank antiseptic and textile dye for blue jeans, it was actually the first synthetic drug in modern history, developed in 1876. Since then, we’ve discovered it has many really important medicinal benefits. The first medical application of methylene blue was for malaria. In 1890, Paul Ehrlich, a scientist at the famous Charité Hospital in Berlin, Germany, discovered methylene blue inhibits an enzyme that weakens the malaria parasite. Methylene blue is approved by the Food and Drug Administration (FDA) as a treatment for methemoglobinemia, a condition that strips hemoglobin of its ability to carry oxygen throughout the body. When this occurs, the body's tissues are deprived of oxygen, resulting in tissue death. Methylene blue helps reverse this condition through a series of steps that res...